These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20412542)

  • 1. Early-stage valuation of medical devices: the role of developmental uncertainty.
    Girling A; Young T; Brown C; Lilford R
    Value Health; 2010 Aug; 13(5):585-91. PubMed ID: 20412542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS.
    Girling A; Lilford R; Cole A; Young T
    Int J Technol Assess Health Care; 2015 Jan; 31(5):331-8. PubMed ID: 26694550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing of medical devices under coverage uncertainty--a modelling approach.
    Girling AJ; Lilford RJ; Young TP
    Health Econ; 2012 Dec; 21(12):1502-7. PubMed ID: 22021085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach.
    Vallejo-Torres L; Steuten LM; Buxton MJ; Girling AJ; Lilford RJ; Young T
    Int J Technol Assess Health Care; 2008; 24(4):459-64. PubMed ID: 18828941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probability elicitation to inform early health economic evaluations of new medical technologies: a case study in heart failure disease management.
    Cao Q; Postmus D; Hillege HL; Buskens E
    Value Health; 2013 Jun; 16(4):529-35. PubMed ID: 23796286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
    Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
    Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Investment Projects of Spinal Medical Device Firms Using the Real Option and DANP-mV Based MCDM Methods.
    Huang CY; Hsieh HL; Chen H
    Int J Environ Res Public Health; 2020 May; 17(9):. PubMed ID: 32403356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early decision-analytic modeling - a case study on vascular closure devices.
    Brandes A; Sinner MF; Kääb S; Rogowski WH
    BMC Health Serv Res; 2015 Oct; 15():486. PubMed ID: 26507131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Health Economic Modelling - Optimizing Development for Medical Device Developers? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Teljeur C; Ryan M
    Int J Health Policy Manag; 2020 Sep; 9(9):403-405. PubMed ID: 32610765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.
    Grimm SE; Pouwels X; Ramaekers BLT; Wijnen B; Knies S; Grutters J; Joore MA
    Pharmacoeconomics; 2020 Feb; 38(2):205-216. PubMed ID: 31709496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic valuation of improved process plant decision support technology.
    White DC
    ISA Trans; 2007 Jun; 46(3):437-42. PubMed ID: 17434170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market Imitation and Win-Stay Lose-Shift Strategies Emerge as Unintended Patterns in Market Direction Guesses.
    Gutiérrez-Roig M; Segura C; Duch J; Perelló J
    PLoS One; 2016; 11(8):e0159078. PubMed ID: 27532219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal timing of multiple investment decisions in a wood value chain: A real options approach.
    Tschulkow M; Compernolle T; Van Passel S
    J Environ Manage; 2021 Jul; 290():112590. PubMed ID: 33910072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices.
    Grimm SE; Dixon S; Stevens JW
    Value Health; 2016; 19(6):720-726. PubMed ID: 27712696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
    Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
    Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic considerations for device design and development.
    Matthews E
    Med Device Technol; 1997 Nov; 8(9):18-26. PubMed ID: 10174626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of new product development in the medical device industry.
    Dixon D; Brown A; Meenan BJ; Eatock J
    Med Device Technol; 2006 Apr; 17(3):20-2. PubMed ID: 16736659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical device market: if it ain't broke, don't fix it.
    Ubl SJ
    Health Aff (Millwood); 2009; 28(3):925; author reply 925. PubMed ID: 19414913
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.